NetworkNewsWire Announces Publication on Gene Therapy’s Promise for Improving Patient Treatments and Market Profitability
March 14 2019 - 8:30AM
via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial
news and publishing company, today announces the publication of an
editorial featuring clinical-stage gene therapy company Genprex
Inc. (GNPX), a client of NNW developing potentially life-changing
technologies for cancer patients based upon a unique proprietary
technology platform, including Genprex’s initial product candidate,
Oncoprex(TM), immunogene therapy for non-small cell lung cancer
(NSCLC).
To view the full publication, titled “Making Profits, Saving
Lives with Gene Therapy,” visit: http://nnw.fm/Y0ZqH
Gene therapy isn’t exactly new. For years, companies such
as Genprex Inc. (NASDAQ: GNPX) have been
working on improvements to the technology and new ways to apply it
in improving and saving lives. The highest profile work has been
done in tackling cancer, an area in which Genprex specializes. The
difficulty of treating cancer, combined with its origin in cell
growth gone bad, makes gene therapy a natural fit for this area.
But plenty of other uses have also been explored over the past
three decades.
If gene therapy has been around for this long, why is now such
an ideal time to invest?
One reason is that the industry has seen a series of mergers and
acquisitions. Small-cap biotech company Spark Therapeutics, which
specializes in gene therapy, was recently bought up by Roche for
$4.8 billion, offering Spark investors a likely gain of 190 percent
for this year. MeiraGTx Holdings, another small-cap gene therapy
company, achieved an $80 million private placement, with Johnson
& Johnson as its lead investor, pushing its shares up 67
percent so far this year. These and other moves show the interest
of big medical companies in gene therapy.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex(TM)
immunogene therapy for non-small cell lung cancer (NSCLC).
Genprex’s platform technologies are designed to administer cancer
fighting genes by encapsulating them into nanoscale hollow spheres
called nanovesicles, which are then administered intravenously and
taken up by tumor cells where they express proteins that are
missing or found in low quantities. Oncoprex has a multimodal
mechanism of action whereby it interrupts cell signaling pathways
that cause replication and proliferation of cancer cells,
re-establishes pathways for apoptosis, or programmed cell death, in
cancer cells, and modulates the immune response against cancer
cells. Oncoprex has also been shown to block mechanisms that create
drug resistance. For more information, visit the company’s website
at www.Genprex.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire
services via NetworkWire to reach all target markets,
industries and demographics in the most effective manner possible,
(2) article and editorial syndication to 5,000+ news outlets, (3)
enhanced press release services to ensure maximum impact, (4)
social media distribution via the Investor Brand Network (IBN) to
nearly 2 million followers, (5) a full array of corporate
communications solutions, and (6) a total news coverage solution
with NNW Prime. As a multifaceted organization with an extensive
team of contributing journalists and writers, NNW is uniquely
positioned to best serve private and public companies that desire
to reach a wide audience of investors, consumers, journalists and
the general public. By cutting through the overload of information
in today’s market, NNW brings its clients unparalleled visibility,
recognition and brand awareness. NNW is where news, content and
information converge. For more information, please visit
https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications Contact:
NetworkNewsWire (NNW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkNewsWire.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024